Numerous studies have shown that the overexpression of the ABC transporters, ABCB1 and ABCG2, in certain types of solid tumors and leukemia, produce acquired drug resistance and attenuate, as well as abrogate, the efficacy of anticancer drugs with different chemical structures and mechanisms of action (Mohammad et al., 2018; Boyer et al., 2019; Wu et al., 2020c; Yang et al., 2021). Here, ABCG2 is linked to leukemia.